@article{curto-barredo_omalizumab_2018,
	title = {Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria},
	volume = {79},
	issn = {1365-2133},
	doi = {10.1111/bjd.16379},
	abstract = {Omalizumab has been shown to be a very effective drug in chronic spontaneous urticaria (CSU) improving patients' quality of life.1 Phase III clinical trials ASTERIA I/II and GLACIAL showed respectively 58.8-52.4\% of patients achieving a twice daily average Urticaria Activity Score 7 (UAS7td)≤6 at week 12.2 Outside of clinical trials, the response varies between 77-83\%.3 However, some patients do not achieve well-controlled activity of the disease with the licensed dose of omalizumab (300mg/4 weeks). This article is protected by copyright. All rights reserved.},
	language = {eng},
	number = {1},
	journal = {British Journal of Dermatology},
	author = {Curto-Barredo, L. and Spertino, J. and Figueras-Nart, I. and Expósito-Serrano, V. and Guilabert, A. and Melé-Ninot, G. and Cubiró, X. and Bonfill-Ortí, M. and Garcias-Ladaria, J. and Villar, M. and García-Navarro, X. and Bielsa-Marsol, I. and Vilavella, M. and Aparicio, G. and Baliu-Piqué, C. and Álvarez, A. and Lamas-Domenech, N. and Duran-Jordà, X. and Serra-Baldrich, E. and Giménez-Arnau, A.},
	year = {2018},
	pmid = {29368377},
	keywords = {Article, Dermatologia},
	pages = {210--212},
}

{"_id":"CmGxyxhfiHBjjACeT","bibbaseid":"curtobarredo-spertino-figuerasnart-expsitoserrano-guilabert-melninot-cubir-bonfillort-etal-omalizumabupdosingallowsdiseaseactivitycontrolinrefractorypatientswithchronicspontaneousurticaria-2018","downloads":0,"creationDate":"2018-10-09T14:45:41.683Z","title":"Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria","author_short":["Curto-Barredo, L.","Spertino, J.","Figueras-Nart, I.","Expósito-Serrano, V.","Guilabert, A.","Melé-Ninot, G.","Cubiró, X.","Bonfill-Ortí, M.","Garcias-Ladaria, J.","Villar, M.","García-Navarro, X.","Bielsa-Marsol, I.","Vilavella, M.","Aparicio, G.","Baliu-Piqué, C.","Álvarez, A.","Lamas-Domenech, N.","Duran-Jordà, X.","Serra-Baldrich, E.","Giménez-Arnau, A."],"year":2018,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria","volume":"79","issn":"1365-2133","doi":"10.1111/bjd.16379","abstract":"Omalizumab has been shown to be a very effective drug in chronic spontaneous urticaria (CSU) improving patients' quality of life.1 Phase III clinical trials ASTERIA I/II and GLACIAL showed respectively 58.8-52.4% of patients achieving a twice daily average Urticaria Activity Score 7 (UAS7td)≤6 at week 12.2 Outside of clinical trials, the response varies between 77-83%.3 However, some patients do not achieve well-controlled activity of the disease with the licensed dose of omalizumab (300mg/4 weeks). This article is protected by copyright. All rights reserved.","language":"eng","number":"1","journal":"British Journal of Dermatology","author":[{"propositions":[],"lastnames":["Curto-Barredo"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Spertino"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Figueras-Nart"],"firstnames":["I."],"suffixes":[]},{"propositions":[],"lastnames":["Expósito-Serrano"],"firstnames":["V."],"suffixes":[]},{"propositions":[],"lastnames":["Guilabert"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Melé-Ninot"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Cubiró"],"firstnames":["X."],"suffixes":[]},{"propositions":[],"lastnames":["Bonfill-Ortí"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Garcias-Ladaria"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Villar"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["García-Navarro"],"firstnames":["X."],"suffixes":[]},{"propositions":[],"lastnames":["Bielsa-Marsol"],"firstnames":["I."],"suffixes":[]},{"propositions":[],"lastnames":["Vilavella"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Aparicio"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Baliu-Piqué"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Álvarez"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Lamas-Domenech"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Duran-Jordà"],"firstnames":["X."],"suffixes":[]},{"propositions":[],"lastnames":["Serra-Baldrich"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Giménez-Arnau"],"firstnames":["A."],"suffixes":[]}],"year":"2018","pmid":"29368377","keywords":"Article, Dermatologia","pages":"210–212","bibtex":"@article{curto-barredo_omalizumab_2018,\n\ttitle = {Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria},\n\tvolume = {79},\n\tissn = {1365-2133},\n\tdoi = {10.1111/bjd.16379},\n\tabstract = {Omalizumab has been shown to be a very effective drug in chronic spontaneous urticaria (CSU) improving patients' quality of life.1 Phase III clinical trials ASTERIA I/II and GLACIAL showed respectively 58.8-52.4\\% of patients achieving a twice daily average Urticaria Activity Score 7 (UAS7td)≤6 at week 12.2 Outside of clinical trials, the response varies between 77-83\\%.3 However, some patients do not achieve well-controlled activity of the disease with the licensed dose of omalizumab (300mg/4 weeks). This article is protected by copyright. All rights reserved.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {British Journal of Dermatology},\n\tauthor = {Curto-Barredo, L. and Spertino, J. and Figueras-Nart, I. and Expósito-Serrano, V. and Guilabert, A. and Melé-Ninot, G. and Cubiró, X. and Bonfill-Ortí, M. and Garcias-Ladaria, J. and Villar, M. and García-Navarro, X. and Bielsa-Marsol, I. and Vilavella, M. and Aparicio, G. and Baliu-Piqué, C. and Álvarez, A. and Lamas-Domenech, N. and Duran-Jordà, X. and Serra-Baldrich, E. and Giménez-Arnau, A.},\n\tyear = {2018},\n\tpmid = {29368377},\n\tkeywords = {Article, Dermatologia},\n\tpages = {210--212},\n}\n\n","author_short":["Curto-Barredo, L.","Spertino, J.","Figueras-Nart, I.","Expósito-Serrano, V.","Guilabert, A.","Melé-Ninot, G.","Cubiró, X.","Bonfill-Ortí, M.","Garcias-Ladaria, J.","Villar, M.","García-Navarro, X.","Bielsa-Marsol, I.","Vilavella, M.","Aparicio, G.","Baliu-Piqué, C.","Álvarez, A.","Lamas-Domenech, N.","Duran-Jordà, X.","Serra-Baldrich, E.","Giménez-Arnau, A."],"key":"curto-barredo_omalizumab_2018","id":"curto-barredo_omalizumab_2018","bibbaseid":"curtobarredo-spertino-figuerasnart-expsitoserrano-guilabert-melninot-cubir-bonfillort-etal-omalizumabupdosingallowsdiseaseactivitycontrolinrefractorypatientswithchronicspontaneousurticaria-2018","role":"author","urls":{},"keyword":["Article","Dermatologia"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["omalizumab","updosing","allows","disease","activity","control","refractory","patients","chronic","spontaneous","urticaria","curto-barredo","spertino","figueras-nart","expósito-serrano","guilabert","melé-ninot","cubiró","bonfill-ortí","garcias-ladaria","villar","garcía-navarro","bielsa-marsol","vilavella","aparicio","baliu-piqué","álvarez","lamas-domenech","duran-jordà","serra-baldrich","giménez-arnau"],"keywords":["article","dermatologia"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}